Latest Investor Relations News

OFX Group Limited has requested a trading halt following significant price and volume spikes in its securities, ahead of its scheduled full year results announcement for FY25.

EDU Holdings has secured ASX approval to voluntarily delist, pending shareholder consent, and announced a $12.4 million equal access share buy-back to provide liquidity options for investors.

Alice Queen Limited has lifted its trading suspension following the announcement of a proposed capital raise, signaling a pivotal moment for the company’s financial strategy.

Gentrack Group Limited reported a solid 9.8% revenue increase and a 34.7% jump in net profit for the first half of 2025, yet opted against paying an interim dividend.

Liontown Resources has responded to an ASX query following a sharp rise in its share price and trading volume, denying any undisclosed information and confirming compliance with listing rules.

Resource Mining Corporation Limited (RMI) has responded to a sharp surge in its share price and trading volume, denying any undisclosed material information while pointing to ongoing copper-gold exploration activities at its Mpanda Project in Tanzania.

Australian Bond Exchange Holdings has completed a $683,180 private placement, issuing over 17 million shares to strengthen its financial position and support expansion and cost-cutting initiatives.

Aspen Group has successfully raised $70.18 million through an institutional placement, aiming to reduce debt and pursue new growth opportunities. A Security Purchase Plan is also underway for eligible investors.

National Australia Bank has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.85 per share for the half-year ending March 2025, payable in multiple currencies.

AKORA Resources has appointed Peter Bird as its new Managing Director and CEO, marking a strategic leadership change aimed at advancing the Bekisopa Iron Ore Project and securing critical funding and partnerships.

Xero Limited reported a robust FY25 with 23% revenue growth to NZ$2.1 billion and a 30% rise in net profit, driven by strategic investments in AI and product innovation. Leadership changes and a CEO pay review underscore the company’s global ambitions.

Mayne Pharma has addressed a sharp share price decline following the public release of an FDA Untitled Letter, confirming no undisclosed material information and reaffirming compliance with ASX rules.